Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein

Cancer Gene Therapy

Volumn 12, Issue 2, 2005, Pages 185-197

  Mincheff, Milcho ^a,d   Zoubak, Serguei ^a   Altankova, Iskra ^b   Tchakarov, Stoyan ^c   Pogribnyy, Petro ^a   Makogonenko, Yevgen ^a   Botev, Chavdar ^d   Meryman, Harold T ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

^c UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^d National Center of Hematology and Transfusion Medicine   (Bulgaria)

Author keywords

CD4+ CD25+ cells; Gene based vaccine; GITR L; Immunodominance; PAP; PSA; T regulatory cells

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CELL PROTEIN; DNA VACCINE; EPITOPE; INTERLEUKIN 2 RECEPTOR ALPHA; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; PROTEASOME; SIGNAL PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; FLOW CYTOMETRY; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNODOMINANCE; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CLONE; LYMPHOCYTE DEPLETION; MOLECULAR CLONING; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; TUMOR CELL; VACCINATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; COS CELLS; DENDRITIC CELLS; EPITOPES; GLYCOSYLATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MONOCYTES; PEPTIDE FRAGMENTS; PHOSPHOPROTEIN PHOSPHATASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-2; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINATION; VACCINES, DNA;

ANIMALIA;

EID: 13444263401     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700778     Document Type: Article

References (53)

1. Mincheff M, Zoubak S, Altankova I, et al. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther. 2003;10:907-917.
2. Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol. 2001;167:7150-7156.
3. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6:1632-1638.
4. Wolchok JD, Gregor PD, Nordquist LT, et al. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol. 2003;30:659-666.
5. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA immunizations for immunotherapy of prostate cancer. In: Annual Meeting of the American Urological Association. 1999 Dallas, TX.
6. Hicklin DJ, Wang Z, Arienti F, et al. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 1998;101:2720-2729.
7. Hiraki A, Kaneshige T, Kiura K, et al. Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. Clin Cancer Res. 1999;5:933-936.
8. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
9. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995;16:487-494.
10. Cordon-Cardo C, Fuks Z, Drobnjak M, et al. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. 1991;51(Part 1):6372-6380.
11. Rivoltini L, Barracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 1995;55:3149-3157.
12. de la Salle H, Zimmer J, Fricker D, et al. HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest. 1999;103:R9-R13.
13. van Duinen SG, Ruiter DJ, Broecker EB, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 1988;48:1019-1025.
14. Schreiber H, Wu TH, Nachman J, et al. Immunodominance and tumor escape. Semin Cancer Biol. 2002;12:25-31.
15. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13:95-109.
16. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol. 1999;17:51-88.
17. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
18. Suri-Payer E, Amar AZ, Thornton AM, et al. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol. 1998;160:1212-1218.
19. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med. 2001;193:F41-F46.
20. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+)t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001;193:1295-1302.
21. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
22. McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16:311-323.
23. Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3:135-142.
24. Kim JD, Choi BK, Bae JS, et al. Cloning and characterization of GITR ligand. Genes Immun. 2003;4:564-569.
25. DeMars R, Chang CC, Shaw S, et al. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol. 1984;11:77-97.
26. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods. 1991;145:185-192.
27. Parker KC, Bednarek MA, Hull LK, et al. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol. 1992;149:3580-3587.
28. Palmowski MJ, Choi EM, Hermans IF, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol. 2002;168:4391-4398.
29. Boden E, Tang Q, Bour-Jordan H, et al. The role of CD28 and CTLA4 in the function and homeostasis of CD4+ CD25+ regulatory T cells. Novartis Found Symp. 2003;252:55-63 discussion 63-56, 106-114.
30. Wang HY, Lee DA, Peng G, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004;20:107-118.
31. Kwon B, Kim BS, Cho HR, et al. Involvement of tumor necrosis factor receptor superfamily(TNFRSF) members in the pathogenesis of inflammatory diseases. Exp Mol Med. 2003;35:8-16.
32. Kohm AP, Williams JS, Miller SD. Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4(+) T cell activation and experimental autoimmune encephalomyelitis. J Immunol. 2004;172:4686-4690.
33. Draenert R, Le Gall S, Pfafferott KJ, et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med. 2004;199:905-915.
34. Bennink JR, Anderson R, Bacik I, et al. Antigen processing: where tumor-specific T-cell responses begin. J Immunother. 1993;14:202-208.
35. Masteller EL, Chuang E, Mullen AC, et al. Structural analysis of CTLA-4 function in vivo. J Immunol. 2000;164:5319-5327.
36. Doyle AM, Mullen AC, Villarino AV, et al. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J Exp Med. 2001;194:893-902.
37. Manzotti CN, Tipping H, Perry LC, et al. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol. 2002;32:2888-2896.
38. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295-302.
39. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303-310.
40. Shevach EM. Regulatory T cells in autoimmmunity*. Annu Rev Immunol. 2000;18:423-449.
41. Groux H, Powrie F. Regulatory T cells and inflammatory bowel disease. Immunol Today. 1999;20:442-445.
42. Sakaguchi S. Regulatory T cells: mediating compromises between host and parasite. Nat Immunol. 2003;4:10-11.
43. Morse MA, Clay TM, Mosca P, et al. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther. 2002;2:827-834.
44. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
45. Jonuleit H, Schmitt E, Stassen M, et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285-1294.
46. Misra N, Bayry J, Lacroix-Desmazes S, et al. Cutting edge: human CD4(+)CD25(+) T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol. 2004;172:4676-4680.
47. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+ CD25+ regulatory T cells. Semin Immunol. 2004;16:89-98.
48. Casares N, Arribillaga L, Sarobe P, et al. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol. 2003;171:5931-5939.
49. Manjili MH, Wang XY, Chen X, et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol. 2003;171:4054-4061.
50. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+ CD25+ immunoregulatory cells. J Immunol. 2001;167:1137-1140.
51. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823-832.
52. Tone M, Tone Y, Adams E, et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci USA. 2003;100:15059-15064.
53. Ronchetti S, Zollo O, Bruscoli S, et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol. 2004;34:613-622.